Talazoparib Formulation Bridging in Cancer Patients-Challenges and the Critical ...

연구 요약

Talazoparib Formulation Bridging in Cancer Patients-Challenges and the Critical Role of Model-Informed Drug Development in Approval Despite Failed Bioequivalence.

CPT: pharmacometrics & systems pharmacology 학술지에 발표된 이 연구는 Wang D, Guo CC, Gao X 외 연구팀이 수행하였습니다.

이 연구는 'Talazoparib Formulation Bridging in Cancer Patients-Challenges and the Critical Role of Model-Informed Drug Development in Approval Despite Failed Bioequivalence.'에 대한 과학적 분석을 제공합니다.

핵심 내용

Talazoparib is a poly(ADP-ribose) polymerase inhibitor approved for the treatment of breast and prostate cancer. Commercialization of a soft gelatin capsule (SGC) formulation developed post-approval required a bioequivalence (BE) and food effect (FE) study to bridge SGC with the initial commercial hard capsule (HC) formulation. Study execution and meeting BE criteria are challenging due to high variability in Cmax, potentially higher Cmax for SGC based on dissolution data, and the need to perform BE/FE assessment at steady state in cancer patients. Model-informed drug development (MIDD) was used to facilitate an efficient/feasible study design. Semi-mechanistic pharmacokinetic (PK)/pharmacodynamic (PD) modeling and simulations showed that AUC, instead of Cmax, drove hematologic events, the main side effects of talazoparib. This supported a BE study powered for AUC equivalence only. Population PK simulation showed that following a 28-day treatment in the first period, 14 days in subsequent periods is sufficient for steady-state BE/FE assessments. Study results showed AUC met BE criteria while Cmax was 37% higher for SGC relative to HC, which was deemed not clinically significant based on the PK/PD model. FE on SGC formulation was consistent with FE on HC formulation reported previously. The safety profile of the two formulations was generally consistent with the known safety profile. The totality of data (AUC equivalence, lack of impact of Cmax on safety, observed safety data) supported bridging of the two formulations although Cmax failed to meet BE criteria. MIDD was critical in study design optimization and supported approval of the SGC formulation. Trial Registration: ClinicalTrials.gov Identifier: NCT04672460.

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41379622)

📄 [전문 보기 (Markdown)](fulltext/41379622-talazoparib-formulation-bridging-in-cancer-patients-challeng.md)